Enhancing the QUAlity and Transparency Of health Research
Search for reporting guidelines
Use your browser's Back button to return to your search results
Minimum Information for Studies Evaluating Biologics in Orthopaedics (MIBO) : Platelet -Rich Plasma and Mesenchymal Stem Cells
| Reporting guideline provided for? (i.e. exactly what the authors state in the paper) |
Reporting of clinical studies evaluating platelet-rich plasma (PRP) and mesenchymal stem cells (MSCs). MIBO PRP checklist (PDF) MIBO stem cells checklist (PDF) |
| Full bibliographic reference | Murray IR, Geeslin AG, Goudie EB, Petrigliano FA, LaPrade RF. Minimum Information for Studies Evaluating Biologics in Orthopaedics (MIBO): Platelet-Rich Plasma and Mesenchymal Stem Cells. J Bone Joint Surg Am. 2017;99(10):809-819. |
| Language | English |
| PubMed ID | 28509821 |
| Reporting guideline website URL | https://www.mibo-statement.org/ |
| Reporting guideline acronym | MIBO |
| Study design | Clinical trials, Experimental studies, Observational studies, Systematic reviews/Meta-analyses/Reviews/HTA/Overviews |
| Clinical area | Rheumatology, Sport and exercise medicine, Surgery |
| Applies to the whole report or to individual sections of the report? | Ethical issues (consent etc.), Harms/adverse effects/safety data, Intervention (exposure), Outcomes (variables), Procedure/Method, Study characteristics (participants etc.) |
| Additional information | Murray IR, Murray AD, Geeslin AG, Goudie EB, White TO, Petrigliano FA, LaPrade RF. Infographic: we need minimum reporting standards for biologics. Br J Sports Med. 2017. PMID: 28831016 |
| Record last updated on | November 25, 2021 |